Comparison of Efficacy and Safety of Sacubitril/Valsartan and Perindopril in Acute Myocardial Infarction Complicated by Post Surgery Heart Failure

Abstract

Hu et al.: Effect of Sacubitril/Valsartan and Perindopril in Acute Myocardial InfarctionThe purpose of this study is to explore the applicability and efficacy of sacubitril/valsartan in individuals with post-percutaneous coronary intervention heart failure subsequent to acute myocardial infarction. 106 individuals with verified acute myocardial infarction diagnosis who underwent percutaneous coronary intervention surgery were selected and divided into two groups with 53 patients in each group. Along with conventional therapy, control group was treated with perindopril, while observation group was treated with sacubitril/valsartan. Before and after treatment, color Doppler ultrasound was harnessed to measure various cardiac function indicators and multifunctional immunoassay analyzer was used to measure myocardial injury biomarkers. Before and after treatment, hemodynamic parameters, encompassing blood pressure, heart rate and the average hourly urine output over a 24 h period, were subjected to comparative analysis between the two groups. Moreover, the evaluation of patients' quality of life was carried out utilizing the Kansas City cardiomyopathy questionnaire, while clinical effectiveness, occurrence of adverse cardiovascular events and readmission within 3 mo of treatment was documented. Before treatment, there is no difference in cardiac function indicators, myocardial injury biomarkers, blood pressure, heart rate, and urine output between the two groups (p>0.05). However, after treatment, the observation group exhibited lower levels of cardiac function indicators, myocardial injury biomarkers, heart rate and higher levels of left ventricular fractional shortening and left ventricular ejection fraction, systolic and diastolic blood pressure and more urine output compared to the control group (p<0.05). The observation group exhibited elevated Kansas City cardiomyopathy questionnaire scores, higher clinical effectiveness and reduced readmission rate compared to the control group. No statistically significant variances (p>0.05) were detected in the incidence of adverse reactions between the two groups. Compared to treatment with perindopril, the use of sacubitril/valsartan can effectively treat acute myocardial infarction complicated with post-percutaneous coronary intervention heart failure.